Insmed reported $73.38M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 24.71M 80.91M Mar/2026
DBV Technologies USD 39.5M 1.44M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026